Hemispherx Biopharma's Ampligen Tested in Combination With Experimental Vaccine From Leading Cancer Research Institute

Hemispherx Biopharma HEB today announced that it has entered into a Material Transfer and Research Agreement with the University of Pennsylvania School of Medicine to provide Ampligen® [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic, for testing as a vaccine adjuvant in a human clinical study in ovarian cancer. The Principal Investigator is Dr. George Coukos who is the Celso Ramon Garcia Associate Professor of Reproductive Biology, Associate Chief of the Division of Gynecologic Oncology, and Director, Ovarian Cancer Research Center, at the University of Pennsylvania School of Medicine Abramson Cancer Center. He is a recognized global leader in ovarian cancer treatment and research. His research focus over the last several years has been on understanding the immune system's response to ovarian cancer, and on developing therapies which enhance that response.